Introduction. The range of medicines with various trade names is extremely large and constantly growing. This is the reason for inadequate selection of medicines and medical errors. The aim: To study the problems of the modern state of medicines naming and to determine the ways of its solution. Materials and methods. General scientific methods of cognition are used: analysis and synthesis, abstraction, deduction, modeling, generalization. The materials were publications from the Google Scholar and PubMed electronic search systems, the Crossref bibliographic database for the period 1984-2024. The following keywords were chosen: medicine and drug, naming, international nonproprietary names, trade name, original drug, generic, brand, branded generic, chemical name, medication error, drug information. Results. It was found that the huge number of trade names of medicinal products causes informational problems with possible clinical consequences. Today, there is no international regulatory system that would guarantee that the trade names of medicines from different manufacturers from different countries differed enough to avoid the risk of incorrect prescriptions due to confusion of their names. It is obvious that the breadth of the modern pharmaceutical market and the huge number of trade names of medicines on it are the reasons for their inadequate selection and medical errors. Conclusions. Based on the results of the study of the problems of the modern system of drug names, the possibility of errors in the use of drugs due to the similarity of their trade names, it is proposed to create, under the auspices of the WHO, a single global system of trade names of drugs based on the globally accepted system of international non-proprietary names, which consists of that the trade name must contain the international non-proprietary name and the name of the manufacturer. The unified global system of trade names of medicines will allow the doctor, pharmacist and patient to choose a generic medicine with a high-quality composition of the active pharmaceutical ingredient and auxiliary substances.

Purpose: Our study aimed to assess the effects of anticancer 4-thiazolidinone-based free water-insoluble therapeutics Les-3288 and
Les-3833 and their waterborne complexes with branched PEG-containing polymeric carriers (A24-PEG550 and A24-PEG750) on
immune response.
Methods: Human peripheral blood was used to study in vitro lymphocyte proliferative function, leukocyte phagocytic activity and
respiratory burst, and cytokine production.
Results: The binding of the polymer to the anticancer drug Les-3288, which is intended to mitigate the immunosuppressive effects of the
free drug on the proliferative activity of T lymphocytes and T-dependent B cells, demonstrated comparable efficacy for both A24-PEG750
and A24-PEG550 nanocarriers. Furthermore, it was observed that the drug-polymer complex significantly increased the reduced levels of
IFN-γ and TNF-α resulting from free Les-3288. Conversely, the reduced levels of IL-6 and IL-4 remained unchanged. Administration of
either form of Les-3288 had no effect on the phagocytic activity of monocytes, granulocytes or the respiratory burst of granulocytes. Due to
the reduced cell viability and increased cytotoxicity associated with Les-3833, tenfold lower doses were selected for the immune assays.
The effects of free Les-3833 on lymphocyte proliferative function resulted in significant stimulation of T-dependent B cells. The binding of
Les-3833 to the smaller carrier, A24-PEG550 was found to maintain the stimulatory effect on B lymphocytes. While no effect of free Les3833 on the granulocyte phagocytic activity was observed, binding of Les-3833 to both polymeric carriers resulted in a decrease in
granulocyte phagocytic activity and respiratory burst, with no observable effect on monocytes. Monitoring of cytokine production showed
no significant effect of either form of Les-3833 on the production of IFN-γ and IL-6. In the context of TNF-α and IL-4, the positive effect of
polymer binding on restoring suppressed cytokine levels induced by the Les-3833 free drug was slightly more favorable for A24-PEG750.
Conclusion: The drug complexation with novel PEGylated carriers is a promising way for efficient therapeutic development.
Keywords: anticancer compounds, lymphocytes, phagocytic activity, respiratory burst, cytokines

In recent decades, the role of hydrogen sulfide (H2S), a gas mediator and signaling agent, has been studied in the regulation of intercellular signaling and intracellular signal transduction pathways with various physiological and pathophysiological effects in cells and tissues. These cellular pathways are responsible for changes in metabolism, epigenetic, and cellular behavior. There are enzymatic and non-enzymatic pathways of endogenous hydrogen sulfide biosynthesis. Numerous studies have shown the diverse effects of H2S on the physiological processes of neurotransmission in the brain, vascular smooth muscle relaxation in synergy with nitric oxide (NO), apoptosis, autophagy, angiogenesis, aging, inflammation, redox system, manifestations of oxidative stress, protein, as well as bioenergetic effects and systemic bioregulatory effects, including ANS. Recently, it was shown that H2S signaling is often dysregulated in different dysfunctions. The effect of H2S on insulin secretion and protection of the heart, kidneys, and brain from ischemic damage, and hypoxia is known. The availability of H2S as a bioregulator has led to changes in cytoprotection, scavenger’s function, and antiinflammatory activities in the digestive system, as well as it could be a molecular target for the creating new safe hybrid compounds, esp., H2S-realized nonsteroidal anti-inflammatory drugs. Our recent research has shown a cytoprotective effect on the mucous membrane of the esophagus and stomach. Thiosulfate sulfurtransferase (TST, EC 2.8.1.1)-derived H2S plays an important role in maintaining redox balance but its effects on mesenteric integrity in aspects of age-related changes and during stress response or high-carbohydrate diet are still limited.

Herein, a method for the coke dry quenching (CDQ) process has been proposed and its optimization has been carried out, which will minimize the disadvantages of this process. This optimization was carried out to develop a technology for uniform coke distribution in the quenching chamber. A model of the real charging device for quenching coke from the Ukrainian enterprise PrJSC “Avdiivka Coke” was developed, and several shortcomings of its operation were shown. It is proposed to use a coke distributor in the form of a bell and a modified bell (specially shaped holes). Graphic mathematical models of the operation of these two devices were developed, and the efficiency of the last of the developed distributors was shown.

Phenolformaldehyde resins were obtained by polycondensation of concentrated phenols with formaldehyde in the presence of hydrochloric acid. Concentration of phenols is carried out by treating the phenolic fraction of coal tar with an aqueous solution of sodium hydroxide followed by neutralization of water-soluble phenolates with hydrochloric acid. The kinetic dependences of resin yield and softening temperature on the duration of the process at 333, 353, and 373 K were obtained. The order of the reaction was determined and the effective activation energy of this process was determined by a graphical method. In the interval 333-373 K for polycondensation reactions, the equation of the dependence of the resin yield on the temperature and duration of the process was obtained.